Prager Martina
Department of Production Molecular Genetics, BAG--BiologischeAnalysensystemGmbH, Lich, Germany.
Transfusion. 2007 Jul;47(1 Suppl):54S-9S. doi: 10.1111/j.1537-2995.2007.01311.x.
DNA-based methods are useful for enhancing immunohematology typings. Ready-to-use Conformité Européenne (CE)-marked test kits based on polymerase chain reaction with sequence-specific priming (PCR-SSP) have been developed, which enable the examination of weak, unexpected, or unclear serologic findings. DEVELOPMENT AND VALIDATION: Primers were designed according to established mutation databases. Proficiency testing for CE marking was performed in accordance with Directive 98/79EC of the European Parliament and of the Council of October 27, 1998 on in vitro diagnostic medical devices using pretyped in-house and external samples. INTENDED USE: BAGene PCR-SSP kits are in vitro diagnostic devices. Genotyping of ABO and RHD/RHCE as well as HPA and KEL, JK, and FY specificities has to be performed after the conclusion of the serologic determination.
Ready-to-use PCR-SSP typing kits allow the determination of common, rare, or weak alleles of the ABO blood group, Rhesus, and Kell/Kidd/Duffy systems as well as alleles of the human platelet antigens.
The investigations showed clear-cut results in accordance with serology or molecular genetic pretyping.
PCR-SSP is a helpful supplementary technique for resolving most of the common problems caused by discrepant or doubtful serologic results, and it is an easy-to-handle robust method. Questionable cases in donor, recipient, and patient typing can be examined with acceptable cost.
基于DNA的方法有助于增强免疫血液学分型。已经开发出了基于序列特异性引物聚合酶链反应(PCR-SSP)的即用型欧洲合格认证(CE)标记检测试剂盒,可用于检测微弱、意外或不明确的血清学结果。
根据已建立的突变数据库设计引物。按照1998年10月27日欧洲议会和理事会关于体外诊断医疗器械的第98/79/EC号指令,使用预先分型的内部和外部样本进行CE标记的能力验证测试。
BAGene PCR-SSP试剂盒是体外诊断设备。ABO和RHD/RHCE以及HPA、KEL、JK和FY特异性的基因分型必须在血清学检测完成后进行。
即用型PCR-SSP分型试剂盒可用于确定ABO血型、恒河猴血型以及凯尔/基德/达菲系统的常见、罕见或微弱等位基因,以及人类血小板抗原的等位基因。
研究结果与血清学或分子遗传预分型结果一致,清晰明确。
PCR-SSP是一种有助于解决大多数由不一致或可疑血清学结果引起的常见问题的辅助技术,是一种易于操作的可靠方法。可以以可接受的成本对供体、受体和患者分型中的可疑病例进行检测。